C4 Therapeutics (NASDAQ: CCCC – Get Rating) and Sana Biotechnology (NASDAQ: SANA – Get Rating) are both small cap medical companies, but what is the best investment? We will compare the two assets based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, and institutional ownership.
Earnings and evaluation
This table compares the revenues, earnings per share and valuation of C4 Therapeutics and Sana Biotechnology.
|Gross Income||Price / sales ratio||Net income||Earning per share||Price / earnings ratio|
|C4 Therapeutic||$ 45.78 million||9.76||– $ 83.89 million||($ 1.82)||-5.04|
|Healthy Biotechnology||N / A||N / A||– $ 355.93 million||($ 2.49)||-3.46|
C4 Therapeutics has higher revenue and earnings than Sana Biotechnology. C4 Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
This table compares the net margins, return on equity and return on assets of C4 Therapeutics and Sana Biotechnology.
|Net margins||Return on equity||Return on assets|
|Healthy Biotechnology||N / A||-35.63%||-24.20%|
This is a breakdown of recent assessments for C4 Therapeutics and Sana Biotechnology, as reported by MarketBeat.
|Sell ratings||Keep the ratings||Buy ratings||Strong purchase ratings||Evaluation score|
C4 Therapeutics currently has a consensus price target of $ 29.10, suggesting a potential upside of 217.34%. Sana Biotechnology has a consensus price target of $ 34.00, suggesting a potential upside of 294.43%. Given the likely more likely upside of Sana Biotechnology, analysts clearly believe that Sana Biotechnology is more favorable than C4 Therapeutics.
Insider and institutional ownership
73.6% of the shares of C4 Therapeutics are owned by institutional investors. Comparatively, 57.4% of the shares of Sana Biotechnology are owned by institutional investors. 21.0% of the shares of C4 Therapeutics are owned by insiders. Strong institutional ownership indicates that hedge funds, large fund managers and endowments believe a company will outperform the market over the long term.
Volatility and risk
C4 Therapeutics has a beta of 2.77, which means that its share price is 177% more volatile than the S&P 500. By comparison, Sana Biotechnology has a beta of 1.4, which means that its share price it is 40% more volatile than the S&P 500.
C4 Therapeutics beats Sana Biotechnology on 10 of the 13 factors compared between the two stocks.
Information on C4 therapy (Get evaluation)
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC protein degrader that is in Phase 1/2 study targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin’s lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and solid tumors cleared by SMARCB1; CFT1946, an orally bioavailable BiDAC degrader targeted at mutant BRAF V600X for the treatment of melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, mutant-selective epidermal growth factor receptor, or EGFR, BiDAC degrader with an L858R mutation in NSCLC; and early stage programs including RET degraders for the treatment of various types of cancer. C4 Therapeutics, Inc. has strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc .; Biogen MA, Inc .; and Calico Life Sciences LLC. The company was formed in 2015 and is headquartered in Watertown, Massachusetts.
About Healthy Biotechnology (Get evaluation)
Sana Biotechnology, Inc., a biotechnology company, focuses on using engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet therapeutic needs, including oncology, diabetes, central nervous system disorders, cardiovascular disease, genetic diseases and others. Its candidate products include SG295 and SG242 which target CD19 + cancer cells, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. Also develops SG418 for sickle cell anemia and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease and Huntington’s disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was formed in 2018 and is headquartered in Seattle, Washington.
Receive news and ratings for C4 Therapeutics every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for C4 Therapeutics and related companies with MarketBeat.com’s FREE daily newsletter.